KM-819
Parkinson's Disease
Key Facts
About FAScinate Therapeutics
FAScinate Therapeutics is a private, pre-revenue biotech founded in 2018, targeting a high-unmet need in neurodegenerative diseases with its lead asset, KM-819. The company's mission is to shift the treatment paradigm for conditions like Parkinson's disease from symptomatic management to disease modification. Operating from the biotech hub of Cambridge, MA, the company is in the clinical development stage and is actively seeking investment and development partnerships to advance its program.
View full company profileAbout FAScinate Therapeutics
FAScinate Therapeutics is a private, pre-revenue biotech founded in 2018, targeting a high-unmet need in neurodegenerative diseases with its lead asset, KM-819. The company's mission is to shift the treatment paradigm for conditions like Parkinson's disease from symptomatic management to disease modification. Operating from the biotech hub of Cambridge, MA, the company is in the clinical development stage and is actively seeking investment and development partnerships to advance its program.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |